Drugs / T-DXd
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04686305 | Mar 2021 → Jun 2027 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04686305 ↗ |
| Route | Intravenous | “T-DXd: administered as an IV infusion” NCT04686305 ↗ |